enhancement of adjuvant functions of natural killer t cells using nanovector delivery systems: application in anticancer immune therapy
Clicks: 149
ID: 219525
2017
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
0.3
/100
1 views
1 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Type I natural killer T (NKT) cells have gained considerable interest in anticancer immune therapy over the last decade. This “innate-like” T lymphocyte subset has the unique ability to recognize foreign and self-derived glycolipid antigens in association with the CD1d molecule expressed by antigen-presenting cells. An important property of these cells is to bridge innate and acquired immune responses. The adjuvant function of NKT cells might be exploited in the clinics. In this review, we discuss the approaches currently being used to target NKT cells for cancer therapy. In particular, we highlight ongoing strategies utilizing NKT cell-based nanovaccines to optimize immune therapy.| Reference Key |
ghinnagow2017frontiersenhancement
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Reem Ghinnagow;Reem Ghinnagow;Reem Ghinnagow;Reem Ghinnagow;Reem Ghinnagow;Luis Javier Cruz;Elodie Macho-Fernandez;Elodie Macho-Fernandez;Elodie Macho-Fernandez;Elodie Macho-Fernandez;Elodie Macho-Fernandez;Christelle Faveeuw;Christelle Faveeuw;Christelle Faveeuw;Christelle Faveeuw;Christelle Faveeuw;François Trottein;François Trottein;François Trottein;François Trottein;François Trottein |
| Journal | sudebno-meditsinskaia ekspertiza |
| Year | 2017 |
| DOI | 10.3389/fimmu.2017.00879 |
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.